Publications by authors named "Sabarinath V Radhakrishnan"

Claim this Profile
P
Plasma Cell Leukemia: Genomic Features and Their Potential Relevance for Exploring Clinical Actionability.
Meera Mohan, Natalie Danziger, Othman Salim Akhtar, Ravi Narra, Marcelo C Pasquini, Sabarinath Venniyil Radhakrishnan

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preventing trogocytosis by cathepsin B inhibition augments CAR T cell function.
Kenneth A Dietze, Kiet Nguyen, Aashli Pathni, Frank Fazekas, Wenxiang Sun, Sabarinath V Radhakrishnan

bioRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients.
Farheen Chunara, Chris Lugo, Kristen Osinski, Mansi R Shah, Nishi Shah, Sabarinath Venniyil Radhakrishnan

Blood Cancer J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma.
Meera Mohan, Aniko Szabo, Anannya Patwari, Jean Esselmann, Tanvi Patel, Sabarinath Venniyil Radhakrishnan

Bone Marrow Transplant· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Lindsay Hammons, Aniko Szabo, Abhishek Janardan, Vineel Bhatlapenumarthi, Evanka Annyapu, Sabarinath Venniyil Radhakrishnan

Haematologica· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study.
Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin, Sabarinath Venniyil Radhakrishnan

Blood Cancer J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restricting CAR T Cell Trafficking Expands Targetable Antigen Space.
Erin A Morales, Kenneth A Dietze, Jillian M Baker, Alexander Wang, Stephanie V Avila, Sabarinath V Radhakrishnan

bioRxiv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study.
Meera Mohan, Anai Kothari, Nathaniel Verhagen, Aditya Shreenivas, Sabarinath Venniyil Radhakrishnan

Bone Marrow Transplant· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity.
Erica R Vander Mause, Jillian M Baker, Kenneth A Dietze, Sabarinath V Radhakrishnan, Thierry Iraguha

Sci Transl Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy.
Samer Al Hadidi, Aniko Szabo, Jean Esselmann, Lindsay Hammons, Munawwar Hussain, Sabarinath Venniyil Radhakrishnan

Bone Marrow Transplant· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.
Meera Mohan, Lisa E Rein, Nishanth Thalambedu, Yetunde Ogunsesan, Munawwar Hussain, Sabarinath Venniyil Radhakrishnan

Am J Hematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Meera Mohan, Melody Renee Becnel, Urvi A Shah, Huaying Dong, Sravani Gundarlapalli, Sabarinath Venniyil Radhakrishnan

Am J Hematol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion.
Michael L Olson, Erica R Vander Mause, Sabarinath V Radhakrishnan, Joshua D Brody, Aaron P Rapoport

Leukemia· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma.
Meera Mohan, Sneha Nagavally, Binod Dhakal, Sabarinath Venniyil Radhakrishnan, Saurabh Chhabra

Blood Adv· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide.
Sabarinath V Radhakrishnan, Tim Luetkens, Sandra D Scherer, Patricia Davis, Erica R Vander Mause

Nat Commun· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab.
Djordje Atanackovic, Sara Yousef, Christa Shorter, Srinivas K Tantravahi, Mary Steinbach, Sabarinath Venniyil Radhakrishnan

Leukemia· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma.
Sabarinath V Radhakrishnan, Michael Boyer, Catherine M Sherwin, Maurizio Zangari, Guido Tricot

Cell Transplant· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of surface molecule CD229 in Multiple Myeloma.
Michael Olson, Sabarinath Venniyil Radhakrishnan, Tim Luetkens, Djordje Atanackovic

Clin Immunol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elotuzumab as a novel anti-myeloma immunotherapy.
Sabarinath Venniyil Radhakrishnan, Neelam Bhardwaj, Mary Steinbach, Janet Weidner, Tim Luetkens

Hum Vaccin Immunother· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation.
Julia Templin, Djordje Atanackovic, Daniel Hasche, Sabarinath Venniyil Radhakrishnan, Tim Luetkens

Oncotarget· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.
Sabarinath Venniyil Radhakrishnan, Neelam Bhardwaj, Tim Luetkens, Djordje Atanackovic

Oncoimmunology· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Strategies for the Immunotherapy of Multiple Myeloma.
Tim Luetkens, Sara Yousef, Sabarinath Venniyil Radhakrishnan, Djordje Atanackovic

Oncology (Williston Park)· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapies targeting CD38 in Multiple Myeloma.
Djordje Atanackovic, Mary Steinbach, Sabarinath Venniyil Radhakrishnan, Tim Luetkens

Oncoimmunology· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
Djordje Atanackovic, Sabarinath V Radhakrishnan, Neelam Bhardwaj, Tim Luetkens

Br J Haematol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population.
Sabarinath Venniyil Radhakrishnan, Gerhard C Hildebrandt

Curr Hematol Malig Rep· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis